National Bleeding Disorders Foundation Secures Code for Glanzmann Thrombasthenia

National Bleeding Disorders Foundation Secures ICD-10-CM Code for Glanzmann Thrombasthenia

In a significant advancement for the medical community, the National Bleeding Disorders Foundation (NBDF), in conjunction with the Glanzmann's Research Foundation and the CHES Foundation, has successfully advocated for the introduction of a dedicated ICD-10-CM code for Glanzmann thrombasthenia. Effective from October 1, 2026, the new code, D69.11, promises to enhance the accuracy of diagnosis and treatment for individuals affected by this rare inherited platelet disorder.

Glanzmann thrombasthenia (GT) is characterized by the blood's inability to clot effectively due to defective platelets. Individuals grappling with this condition often encounter recurrent bleeding issues, manifesting as frequent nosebleeds, easy bruising, and sometimes life-threatening complications. Despite the severe implications for patients' health, GT had previously been lumped together under a broader coding category that overlooked its unique characteristics and treatment requirements, potentially leading to underdiagnosis and inadequate care.

The advocacy for a specific ICD-10-CM code stemmed from discussions involving HEMAB Therapeutics and other key stakeholders, who identified major challenges in recording and analyzing healthcare data related to Glanzmann thrombasthenia. This lack of precise identification complicated efforts for medical research and healthcare accessibility, which are crucial for improving patient outcomes. It became increasingly clear that more effective tracking and documentation were essential not only for patient care but also for public health data collection.

With the introduction of D69.11, healthcare professionals will benefit from a precise coding system that supports clearer communication in medical records, insurance claims, and research. Better documentation is expected to lead to more consistent billing practices and improved insurance coverage decisions, ultimately enabling more effective treatments and patient management strategies. Additionally, D69.11 will facilitate improved identification of GT patients for clinical studies and enhance tracking of health outcomes over time.

This new coding system is particularly vital for addressing the complex needs of individuals with Glanzmann thrombasthenia. Patients often experience interruptions to their daily lives due to the unpredictable nature of their bleeding episodes, which can lead to chronic anemia, missed school or work, and extensive healthcare requirements. The establishment of a dedicated code reflects the necessity for a tailored approach in healthcare practices that address the unique challenges faced by these patients.

The advocacy process leading to this landmark achievement began in earnest in 2024 with the submission of the request to the Centers for Disease Control and Prevention's National Center for Health Statistics (NCHS). Following a review in 2025, the approval was granted, paving the way for implementation in 2026. This initiative perfectly showcases the NBDF's steadfast commitment to advancing research and ensuring appropriate healthcare access for individuals living with rare bleeding disorders.

Maria E. Santaella, Senior Vice President of Research Strategy at NBDF, commented on this significant milestone, stating, "This achievement reflects what NBDF is uniquely positioned to do: bring together clinical expertise, research evidence, and advocacy to address the pressing challenges faced by individuals with rare bleeding disorders. With a dedicated code, we can ensure that Glanzmann thrombasthenia patients are counted, studied, and better served."

About the National Bleeding Disorders Foundation (NBDF)

Founded with the mission of eliminating inherited blood and bleeding disorders, the National Bleeding Disorders Foundation (NBDF) is committed to discovering cures and providing effective management strategies through research, education, and advocacy. NBDF supports individuals across the United States living with various bleeding disorders, including hemophilia and platelet disorders. The organization has evolved from its previous identity as the National Hemophilia Foundation to further encompass the wide spectrum of bleeding disorders under its advocacy umbrella.